top of page

PUBLICATIONS

21. Miller, S. J., Walaieh, S., Lewis, J. A., & Logan, R. Senolytic and senomorphic secondary metabolites as therapeutic agents in D. melanogaster models of Parkinson's disease. Front. Neurol., 28 Seprember 2023: 14

20. Ji Cai-Fang, Wu Guan-Hui, Du Xiang Dong, Wang Gui-Xian, Liu Li-Li, Niu Mei-E., Logan Robert, Kong Fan-Zhen. Factors that contribute to trait mindfulness level among hospitalized patients with major depressive disorder. Front. Psychiatry., 29 June 2023: 14

19. Miller J.M., Campbell C.E., Jimenez-Corea H.A., Wu G.H., Logan R. Neuroglial senescence, alpha-synucleinopathy, and the therapeutic potential of senolytics in Parkinson’s disease. Front. Neurosci., 19 April 2022: 514

18. Logan R., Fleischmann Z., Annis S., Wehe A.W., Tilly J.L., Woods D.C., Khrapko K. 3GOLD: Optimized Levenshtein Distance for Clustering Third-Generation Sequencing Data. BMC Bioinformatics 23, 95 (2022)

17. Logan R., Zerbey S.S., Miller S.J. "The Future of Artificial Intelligence for Alzheimer’s Disease Diagnostics." Advances in Alzheimer's Disease 10.4 (2021): 53-59

16. Kong F., Ji C., Du X., Logan R., Zhao H., Wu G., Liu Y., Tang Z., Niu M., Baseline beliefs about medication are associated with outcomes of antidepressants in patients with first-diagnosed depression under supervised therapeutic compliance. Aging (Albany NY) 2021; 13.17:21400

15. Logan R., Williams B.G., Da Silva M.F., Indani A., Schcolnicov N., Ganguly A., Miller S.J. Deep convolutional neural networks with ensemble learning and generative adversarial networks for Alzheimer’s disease image data classification. Frontiers in Aging Neuroscience. 2021; 13, 497.

14. Peters OM, Weiss A, Metterville J, Song L, Logan R, Smith GA, Schwarzschild MA, Mueller C, Brown R, Freeman M. Genetic diversity of axon degenerative mechanisms in models of Parkinson’s disease. Neurobiology of Disease. 2021 Apr 20: 105368

13. Kong FZ, Wang Y, Wang MX, Cheng QZ, Logan R, Wu GH, Hu SM. Clinical characteristics of the first known cases of death caused by COVID-19 pneumonia. Aging (Albany NY). 2020 Nov; 12(22): 22405-22412

12. Annis S, Fleischmann Z, Logan R, Mullin-Bernstein Z, Franco M, Saurich J, Tilly JL, Woods DC, Khrapko K. LUCS: a high-resolution nucleic acid sequencing tool for accurate long-read analysis of individual DNA molecules. Aging (Albany NY). 2020 Apr; 12(8): 7603-7613

11. Schwarzschild MA, Macklin EA, Bakshi R, Battacharyya S, Logan R, Espay AJ, Hung AY, Bwala G, Goetz CG, Russell DS, Goudreau JL. Sex differences by design and outcome in the Safety of Urate Elevation in PD (SURE-PD) trial. Neurology. 2019 Sep 4:10-212

10. Kastanenka K.V., Calvo-Rodriguez M., Hou S.S., Zhou H., Takeda S., Arbel-Ornath M., Lariviere A., Lee Y.F., Kim A., Hawkes J.M., Logan R., Feng D., Chen X., Gomperts S.N., Bacskai B.J. Frequency-dependent exacerbation of Alzheimer’s disease neuropathophysiology. Scientific Reports. 2019 June; 9(1):8964

9. Bakshi R., Macklin E.A., Logan R., Zorlu M.M., Xia N., Crotty G.F., Zhang E., Chen X., Ascherio A. and Schwarzschild M.A. Higher urate in LRRK2 mutation carriers resistant to Parkinson's disease. Annals of neurology. 2019 April; 85(4): 593-599

8. Chen X, Umeh CC, Tainsh RE, Feng DD, Maguire M, Zuo F, Rahimian M, Logan R, Wang X, Ascherio A, Macklin EA. Dissociation between urate and blood pressure in mice and in people with early Parkinson's disease. EBioMedicine. 2018 Nov; 37:259-268.

7. Chen X, Chen H, Cai W, Maguire M, Ya B, Zuo F, Logan R, Li H, Robinson K, Vanderburg CR, Yu Y, Wang Y, Fisher DE, Schwarzschild MA. The melanoma-linked “redhead” MC1R influences dopaminergic neuron survival. Ann Neurol. 2017 Mar;81(3):395-406

6. Kastanenka KV, Hou SS, Shakerdge N, Logan R, Feng D, Wegmann S, Chopra V, Hawkes JM, Chen X, Bacskai BJ. Optogenetic restoration of disrupted slow oscillations halts amyloid deposition and restores calcium homeostasis in an animal model of Alzheimer's disease. PLoS One. 2017 Jan 23;12(1):e0170275

5. Bhattacharyya S, Bakshi R, Logan R, Ascherio A, Macklin EA, Schwarzschild MA. Oral inosine persistently elevates plasma antioxidant capacity in Parkinson’s disease. Mov Disord. 2016 March; 31(3):417-21.

4. Bakshi R, Zhang H, Logan R, Joshi I, Chen X, Schwarzschild MA. Neuroprotective effects of urate are mediated by augmenting astrocytic glutathione synthesis and release. Neurobiol Dis. 2015 Oct; 82: 574-9.

3. The Parkinson Study Group SURE-PD Investigators; Schwarzschild MA, Ascherio A, Beal MF, Cudkowicz ME, Curhan GC, Hare JM, Hooper DC, Kieburtz KD, Macklin EA, Oakes D, Rudolph A, Shoulson I, Tennis MK, Espay AJ, Gartner M, Hung A, Bwala G, Lenehan R, Encarnacion E, Ainslie M, Castillo R, Togasaki D, Barles G, Friedman JH, Niles L, Carter JH, Murray M, Goetz CG, Jaglin J, Ahmed A, Russell DS, Cotto C, Goudreau JL, Russell D, Parashos SA, Ede P, Saint-Hilaire MH, Thomas CA, James R, Stacy MA, Johnson J, Gauger L, Antonelle de Marcaida J, Thurlow S, Isaacson SH, Carvajal L, Rao J, Cook M, Hope-Porche C, McClurg L, Grasso DL, Logan R, Orme C, Ross T, Brocht AF, Constantinescu R, Sharma S, Venuto C, Weber J, Eaton K. Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial. JAMA Neurol. 2014 Feb 1;71(2):141-50.

2. Chen X, Burdett T, Desjardins CA, Logan R, Xu Y, Cipriani S, Schwarzschild MA. Disrupted and transgenic urate oxidase alters urate and neurodegeneration in a mouse model of Parkinson’s disease. Proc Natl Acad Sci U S A. 2013 Jan;110(1):300-5

1. Burdett T, Desjardins CA, Logan R, McFarland NR, Chen X, Schwarzschild MA. Efficient determination of purine metabolites in brain tissue and serum by high-performance liquid chromatography with electrochemical and UV detection. Biomed Chromatogr. 2013 Jan;27(1):122-9

bottom of page